Our Lady's Hospice & Care Services

Reports and Financial Statements for the financial year ended 31 December 2021

REPORTS AND FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

CONTENTS

	PAGE
DIRECTORS AND OTHER INFORMATION	2
DIRECTORS' REPORT	3 - 14
DIRECTORS' RESPONSIBILITIES STATEMENT	15
INDEPENDENT AUDITORS' REPORT	16 - 18
STATEMENT OF FINANCIAL ACTIVITIES	19
BALANCE SHEET	20
STATEMENT OF CASH FLOWS	21
NOTES TO THE FINANCIAL STATEMENTS	22 - 48

DIRECTORS AND OTHER INFORMATION

DIRECTORS Lorcan Birthistle (Chairperson)

Kay Connolly
Sean Dorgan
Helen Nolan
Dr. Terry McWade
Eugene Murray
Carole Pollard
Dr. Philip Wiehe
Catherine Maguire
Vincent Barton
Hilary Coates
Dermot Ryan

Pat Costello

CHIEF EXECUTIVE OFFICER Audrey Houlihan

CHARITY REGISTRATION NUMBER 20001827

CHARITY TAX NUMBER CHY1144

COMPANY REGISTRATION NUMBER 352404

COMPANY SECRETARY Helen Nolan

REGISTERED OFFICE Our Lady's Hospice

Harold's Cross Dublin 6W

AUDITORS Deloitte Ireland LLP

Chartered Accountants and Statutory Audit Firm Deloitte & Touche House, Earlsfort Terrace

Dublin 2

BANKERS Bank of Ireland

1 Rathfarnham Road Terenure, Dublin 6

SOLICITORS Woodcock Solicitors

Pembroke Hall

38-39 Fitzwilliam Square

Dublin 2

Beauchamps Riverside Two

Sir John Rogerson's Quay

Dublin 2

DIRECTORS' REPORT

The directors present their annual report and the audited financial statements for the financial year ended 31 December 2021.

PRINCIPAL ACTIVITIES

Our Lady's Hospice & Care Services (OLH&CS) has three facilities, Harold's Cross, Blackrock and Wicklow, where specialist care is provided for people with a range of needs from rehabilitation to end of life care. These services are provided in co-operation with the Health Service Executive (HSE) and the Department of Health. The company also fundraises to continue to develop the campus, to enhance patient services and to repay bank debt relating to Wicklow Hospice. The effects of the COVID-19 virus pandemic along with the HSE cyber attack were seen throughout the 2021 financial year and continue into 2022. The principal activities of the company are summarised below:

Palliative Care

Our Lady's Hospice & Care Services offers person-centred specialist Palliative Care to people with advanced life-threatening illness, end of life care and symptom management in inpatient, outpatient and community settings.

Community Reablement Unit, CRU

The Community Reablement Unit (CRU) is a unique intermediate care programme, specially designed to help those 65 years of age or over to live independently in the local community.

Care of Older Persons in Anna Gaynor House

Care of Older Persons and Extended Care Services are provided at Anna Gaynor House which is a purpose-built residential unit for those with supportive palliative care needs or high dependent long-term care.

Rheumatic & Musculoskeletal Disease Unit, RMDU

The Rheumatic & Musculoskeletal Disease Unit provides a unique service to people with chronic rheumatologic and musculoskeletal conditions requiring specialist medical management and rehabilitation.

Education & Research

Education, research and training form the bedrock for a quality service to patients and their families. Education courses, seminars and workshops are provided throughout the year. The state-of-the-art facilities are also available to hire. In addition, significant research activity takes place onsite which directly links to the provision of evidence based care.

Fundraising & Communications

The company's achievements in specialist person centred care are built upon the generous donations and fundraising of thousands of individuals, groups and companies across a number of campaigns and events every year. Thanks to their compassion, commitment and generosity, along with the funding allocation received from the HSE, the organisation is able to continue to develop the infrastructure and facilities and provide high quality care on a consistent basis. Our Communications programme continues to raise our profile, strategically supports our fundraising activities and celebrates the stories of the patients, residents and families with whom we work.

DIRECTORS' REPORT (CONTINUED)

RESULTS FOR THE FINANCIAL YEAR

The directors are satisfied with the results for the financial year. Our Lady's Hospice & Care Services recorded an overall surplus of €938,695 in the year to 31st December 2021, compared to a surplus of €6,586,878 in the previous year. There is a sizeable decrease in the reported surplus in 2021, however, the surplus in the previous year is largely attributable to the accounting treatment of the transfer of Wicklow Hospice which is a non-recurring item in 2021.

Covid continues to have a significant impact in 2021 and whilst there was a slight increase in both RMDU and Palliative Care private health insurance income from the previous year, we are still €2m down on pre pandemic levels of Income. As we move into 2022 we have secured agreement with the HSE for a new acute service level agreement that will address the funding shortfall in our Rheumatic & Musculoskeletal Disease Unit. This has enabled us to improve and enhance our model of care and will greatly enhance and develop our ability to meet the needs of our patients in the years to come. We have also secured baseline funding for the Wicklow unit which has enabled us to continue to support the needs of the community which we serve in both our in patient and community palliative care teams in the region.

The Statement of Financial Activities highlights the results between restricted and unrestricted activities. Restricted activities relate to all HSE funded healthcare activities along with restricted income and expenditure arising from donated funds from the public which were donated for a specific activity or purpose.

Fundraising activities generated income of €6.9m (up from €4.8m in 2020) of which €1.6m was used to supplement pay and non-pay expenditure for healthcare activities in order to maintain the same level of care and services to patients as previous years.

The cash inflow from operating activities for the financial year was €4.4m.

The company had €14.6m of cash at bank excluding €188,402 of 3rd party funds (see note 21 for breakdown) at the financial year end of which €26k related to investment cash. These cash balances together with the investment portfolio of €0.2m are available for the future development of the healthcare facilities in line with our master development plan and also for maintaining the level of services at the current levels for the foreseeable future. As per the master development plan we have already committed €6,968,899 of these monies towards the refurbishment of Blackrock which will greatly enhance our clinical infrastructure to the benefit of our patients.

DIRECTORS' REPORT (CONTINUED)

RESULTS FOR THE FINANCIAL YEAR (CONTINUED)

Funds held by the company at year-end are represented as follows:

	Total 2021	Total 2020
	€	2020
Share capital and premium	38,638,788	38,638,788
Restricted capital funds - HSE related	19,665,992	20,662,561
Restricted capital funds - Donor related	6,088,177	3,592,501
Restricted funds – HSE related	1,067,299	1,104,924
Restricted funds – Donor related	176,288	137,567
Unrestricted funds – OLH&CS	32,299,759	32,861,267
Total funds at end		
of financial year	97,936,303	96,997,608

DIVIDENDS

The company is precluded by its Memorandum of Association from paying dividends either as part of normal operations or on a distribution of its assets in the event of a winding-up.

FUTURE DEVELOPMENTS

Strategic Plan

Our five-year strategic plan to enhance our care 2017 – 2022 demonstrates the progressive vision of the directors, management and staff for providing high quality and safe services for all of our patients, residents and clients, and developing those services in line with best national and international practice. The plan is focused on building on our previous strategy and reputation, through strong clinical and corporate governance and working in collaboration with our partners. It includes incremental growth and change, including the provision of nursing clinical governance to St. Brigid's Hospice Kildare. We passionately believe that everyone living in our community should be able to access high quality, excellent and person-centred care when they need it. Based on our values, we believe that our services should be delivered in the most appropriate and effective way to respond to the needs of the individual and their family. Changes to the model of care within our specialisms supported delivery of care to increased numbers of outpatients with a focus on meeting current and future demand.

We acknowledge that there will be challenges and risks as we adapt and align existing funding models and strive to ensure that we have capacity both in workforce and facilities, to meet service needs and support areas of growth. This strategy also places a huge emphasis on strong healthcare governance and compliance ensuring efficiency and accountability so that those depending upon and supporting Our Lady's Hospice & Care Services can be assured of the highest quality standards and transparency in all that we do.

DIRECTORS' REPORT (CONTINUED)

FUTURE DEVELOPMENTS (CONTINUED)

Master Development Plan

Our Lady's Hospice & Care Services is working through an ambitious Master Development Plan. Liaising with and receiving the support of key funders and donors to raise sufficient funds to complete the plan is of critical importance to the improvement of the quality of care services provide by Our Lady's Hospice & Care Services.

During 2021 preparation for the refurbishment and upgrade of the 12 bedrooms and ancillary services in Blackrock Hospice commenced with the inpatient unit relocating to Harold's Cross and community team to a temporary site in Merrion. Building works have commenced and are estimated to conclude in Q3 2022 at a cost of €6,968,899.

The scoping out of the development of a new Community focused out-patients model of care concluded in 2021, thus enabling us to see more patients in the most effective, efficient and appropriate setting for their needs. Scoping for the redesign of Anna Gaynor House to comply with HIQA single room requirements has also commenced, including seeking support within the HSE capital plan.

Initial scoping commenced to update our capital master development plan and to review our model of care to address future demand and to provide increased outpatient services across all our specialisms. We concluded a consultative process facilitated by external expertise.

Care Services

The directors continue to allocate fundraising income in order to maintain service levels at our care facilities and to develop our care facilities and are eternally grateful to all our supporters and donors for their on-going support. It is the directors' intention over the coming years to develop and expand our services so that we meet the needs of our changing society while never losing sight of the core values of Our Lady's Hospice & Care Services.

The directors acknowledge with gratitude the on-going support of our donors, fund-raisers, volunteers and the HSE in enabling them to continue to enhance and develop the services at Our Lady's Hospice & Care Services.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The directors are responsible for the management of the business of the company and for exercising their powers in pursuit of the charitable objects of the company. The directors are committed to maintaining a very high standard of Corporate Governance and they believe that this is a key element in ensuring the proper operation of the company's activities.

DIRECTORS' REPORT (CONTINUED)

STRUCTURE, GOVERNANCE AND MANAGEMENT (CONTINUED)

Our Lady's Hospice & Care Services must maintain various standards of compliance including with the HSE's Service Level Agreement, the Companies Acts, Director's Compliance Statement and the Charities Regulatory Authority Governance Code. Furthermore, there is a significant emphasis placed on robust healthcare, clinical, corporate and financial governance, compliance, legislation, regulation, inspection, and internal and external audit functions to ensure accountability and transparency.

The Board is responsible for providing leadership, setting strategy and ensuring control and overseeing performance management, talent management and secession planning strategies. There is currently 13 non-executive directors who are drawn from diverse backgrounds and bring their expertise and decision-making skills to the Board deliberations.

The company has a comprehensive process for reporting management information to the Board. The Board is provided with regular information for all aspects of the organisation.

To support their governance activities the Board has established a number of Committees, who report directly to the Board. Each Committee has its own terms of reference. The Committees of the Board are the Mission Committee, the Education & Research Committee, the Audit & Finance Committee, the Clinical Governance Committee, the Fundraising Committee, the Capital Committee, the Nominations Committee and the Remuneration Committee. The primary purposes and functions of each Committee is set out below:

The Mission Committee

- o To promote the Mission and Vision of OLH&CS to ensure it is translated into every aspect of the daily running of the organisation
- To ensure that the core values of OLH&CS of Human Dignity; Compassion; Justice; Quality; and,
 Advocacy continue to shape and guide the decisions and direction of the organisation
- o To welcome, recognise, appreciate and embrace the contribution made by people of all faiths, traditions and backgrounds, as well as providing for those beliefs and traditions

Education and Research Committee

- o To develop policy and strategy in relation to Education, Research and Training
- To oversee the implementation of programmes
- o To develop and manage sub committees of the E&R Committee for the purpose of approval and funding of research initiatives and/or other specific purposes

• Audit & Finance Committee

- To provide independent, objective and timely advice to the Board on the financial reporting process and the judgements associated therewith to ensure the balance, transparency and integrity of the business
- o To oversee and advise on Corporate Risks across the company
- To review the scope and effectiveness of internal financial controls and risk management systems, and the internal and external audit functions

DIRECTORS' REPORT (CONTINUED)

STRUCTURE, GOVERNANCE AND MANAGEMENT (CONTINUED)

Clinical Governance Committee

- o To ensure an effective system of integrated governance, high quality improvement initiatives, and clinical risk management across all the activities that support the company's objectives.
- o To ensure that appropriate clinical and non-clinical risk management arrangements are in place for the company.
- o To ensure compliance with laws and regulations and to ensure effective implementation of the hospital risk management policy

Fundraising Committee

- To provide strategic direction and lead on the implementation of the company's ambitious plans to transform specialist community based services for another generation of patients and deliver upon our vision.
- To drive OLH&CS's evolving vision for the future of service delivery
- o To raise awareness of OLH&CS's needs and goals, to develop relationships and opportunities and to establish capacity within OLH&CS for fulfilment of same

Nominations Committee

- To give full consideration to secession planning for non-executive directors and in particular for the key role of chief executive
- o To identify and nominate suitable candidates for the role of Board Sub-Committee members
- To re-appoint any non-executive director at the conclusion of their specified term of office having given due regard to their performance and ability to continue to contribute to the Board in the light of the knowledge, skills and experience required

Capital Committee

- To coordinate efforts to oversee the planning of capital developments and to assist the Board of Directors in prioritising and identifying resources for future capital development
- o To identify, discuss and act on emerging issues, initiatives, and projects related to capital
- To develop and recommend a capital plan to support the successful delivery of healthcare in a high quality environment

• Remuneration Committee

- o To review remuneration and benefits policy generally
- o To have oversight of any senior level salary above €65k and ensure compliance with Department of Health consolidated payscales
- o To review annual expenses of the Senior Management Team

MANAGEMENT

The senior management team is made up of our CEO - Audrey Houlihan; Director of Finance - Simon Costello (resigned August 2021, Interim Director of Finance - John Fogarty); Chief Operations Officer - Mary Flanagan; Medical Director - Dr. Stephen Higgins; Director of Non Clinical Services - Tommy Beatty; Director of HR - Mary Kirwan and Director of Fundraising and Communications - Eleanor Flew.

DIRECTORS' REPORT (CONTINUED)

STAFF AND VOLUNTEERS

Our Lady's Hospice and Care Services could not function and provide the level of care and support to patients and relatives without the commitment of the Staff and the Volunteers. The directors wish to express their huge gratitude to all Staff and Volunteers for the excellent care that they provide.

PRINCIPAL RISKS AND UNCERTAINTIES

The directors, in conjunction with the senior management team, follow a process to manage the risks to which the company is exposed. They particularly concern themselves with operational and financial risks. They are satisfied that appropriate systems are in place to mitigate against these risks, and limit exposure. Risks are identified and ranked in terms of potential impact, as well as the company's risk control measures. Major risks are those which may have an impact on operational performance, financial sustainability, achievement of aims and objectives and meeting expectations of our patients, funders and supporters.

The principal risks and uncertainties that the company faces are:

- Clinical risks to patients under our care, either as inpatients or in their usual home environment:
 These risks are mitigated by the use of appropriately qualified and trained clinical staff, working within safe systems of care, having appropriate equipment which reduces risk, such as automated equipment to prevent human error, having appropriate policies and procedures in place and our incident reporting system which includes reporting near misses so that future incidents can be prevented. We have adequate cover in place for public and clinician liability under State Claims agency and Clinical Indemnity schemes.
- Failure to comply with Statutory/ Regulatory Requirements: The company is subject to stringent
 regulations in areas such as staff competency, staffing levels, health & safety matters and has
 appropriate processes in place to monitor adherence and compliance with legislation and regulations
 impacting on its operations.
- Financial dependency on the HSE: The company is dependent on the ongoing support of the HSE for
 funding to deliver care services. Ongoing funding at an appropriate level is fundamental to the
 company's ability to continue as a going concern. It is company policy to mitigate this risk by developing
 ongoing relationships with the HSE and agreeing annually our Service Level Agreement.
- Lack of funding for future development of the campus: The company has ambitious plans to better utilise the space available on the campus and enhance patient care. There is a risk that insufficient funding will be available to complete the construction as set out in the Master Development Plan. Liaising with the HSE is ongoing in relation to funding of these developments, along with continued increases in fundraising reserves for capital use.
- Fundraising Risk: The above development funding risk is linked to a general fundraising risk of potential lower donations or bequests which would impact on our ability to both carry out these developments and also to maintain the same levels of quality and service.
- General Data Protection Regulation: Our Lady's Hospice & Care Services continue to implement GDPR
 regulations in an effort to achieve compliance. Risk assessments and risk minimization actions are put
 in place to minimize areas of non-compliance and the Board are advised regularly on implementation
 progress and gap analysis. OLH&CS currently has a contract with a third party (Ambit Compliance) who

DIRECTORS' REPORT (CONTINUED)

review existing OLHCS policies and reports quarterly to Audit and Finance committee. Security and privacy policies and procedures in place including ICT policies to mitigate any risks.

- Insufficient funds to meet pension payments: The company is dependent on the Department of Health to continue to provide the funds required to pay current pension liabilities, under the VHSS, as they arise into the future. There have been no retirements to date from the Single Public Service Pension Scheme (SPSPS).
- COVID-19: The directors have considered the negative impacts of the global COVID-19 virus pandemic on the company. There is a strong possibility that the company's main sources of income will continue to be affected. This is covered in detail under Going Concern below.

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The company's activities expose it to a number of financial risks including credit risk, cash flow risk and liquidity risk. These are disclosed in Note 27 to the financial statements.

RESERVES POLICY

The key principle is that our reserves on non-HSE funded activities should be sufficient to manage a severe situation in which our cash inflows significantly fail to meet our cash outflows. In such a "worst case" scenario, the reserves can be drawn upon in order to meet operating cash shortfalls, specifically the payroll costs associated with non-HSE funded staff members. In general, working capital reserves of €0.8m are held along with payroll reserves of €1.25m. In addition to this, any additional cash available is primarily held in order to meet future capital expenditure requirements or other needs as may arise from time to time. Detailed cash forecasting analysis is undertaken in order to effectively manage reserves and spending of same.

RESEARCH AND DEVELOPMENT

The company carries out on-going research to achieve optimum care for patients.

EUROPEAN COMMUNITIES (LATE PAYMENT IN COMMERCIAL TRANSACTIONS) REGULATIONS 2012

The directors have put procedures in place which provide reasonable assurance that the company is complying in all material respects with the Prompt Payments of Account Act, 1997 and European Communities (Late payment in Commercial Transactions) Regulations 2012, in so far as is permitted by cash flow constraints.

DIRECTORS' REPORT (CONTINUED)

GOING CONCERN

The company's business activities, together with the factors likely to affect its future development, performance and position are set out in the Directors' Report.

The financial statements have been prepared on the going concern basis. The company is dependent on the Health Service Executive (HSE) to fund its activities and the ongoing support of the HSE at an appropriate level is fundamental to the company's ability to continue as a going concern. The HSE has not given any indication that it will withdraw its financial support from the company for the foreseeable future and has continued to provide funding for 2022. The HSE has indicated that funding will be available during 2022 at a level similar to that of 2021.

During 2021 Ireland continued to be impacted by the COVID pandemic. The directors have again considered the COVID impact on the company, and they recognise that there is still a risk that fundraising activities may continue to be disrupted or curtailed by the ongoing impact of the pandemic.

While our organisation has shown great resilience in terms of our fundraising ability over the last 26 months or so since the first closures arising from Covid 19, we continue to operate in a challenging fundraising environment. Our fundraising income held up very well during 2021, and while we continue to be conservative in our estimates of fundraising income for 2022 and 2023 due to the ongoing curtailment of certain in-person events and activities, we are optimistic that the lost income from such in-person events will be lower in 2022 and 2023 than the preceding two years. We are also conscious that other world events and fundraising campaigns around for example the Ukraine crises may impact on our donor pool.

Funding pressures and breaking even on HSE funded activities remain a concern, especially in relation to reduced private health insurance income which improved marginally on 2021 but is still almost €1.8m below pre pandemic levels. This is coupled with an increased demand for the company's services. Management have reviewed the level of activity and costs of the company and have drawn up plans to deal with the issues associated with the ongoing funding pressures. The company's current operating budget and forecast (assuming no reduction in HSE Funding) show that the company should be able to operate within its available funding for the foreseeable future (at least twelve months from the date of approval of these financial statements).

While the strong reserves position at year-end means that there is no immediate threat to the going concern status of OLH&CS, provision of services remains reliant on funding from the HSE continuing at the same or enhanced levels in the future.

After making due enquiries, the directors have a reasonable expectation that the operating and capital budgets and plans will be achieved and that the company will have adequate resources and sufficient liquidity to continue to operate for the foreseeable future. On that basis, the directors have continued to adopt the going concern basis of accounting in preparing these financial statements.

The ongoing support of the HSE at an appropriate level and the generosity of the public are fundamental to the achievement of these plans.

DIRECTORS' REPORT (CONTINUED)

POST BALANCE SHEET EVENTS

The directors have considered the impact of the situation arising from the invasion of Ukraine by Russia, and the consequent sanctions imposed on the latter, are generating impacts on the global economy that, at the date of preparation of these financial statements, are unpredictable.

In this context, the world economy is affected by the increase in the prices of certain goods and services. Management have, and will continue to, monitor these changes in the context of overall expenditure review and considerations.

DIRECTORS AND SECRETARY

The directors and secretary, who served at any time during the financial year except as noted, were as follows:

Directors:

Lorcan Birthistle (Chairperson)

Helen Nolan

Pat Costello

Kay Connolly

Sean Dorgan

Dr. Terry McWade

Eugene Murray

Carole Pollard

Dr. Philip Wiehe

Catherine Maguire

Vincent Barton

Hilary Coates (appointed 27/09/21)

Dermot Ryan (appointed 27/09/21)

Brian Murray (resigned 27/09/21 (outgoing Chairperson)

Stephen Walsh (resigned 27/09/21)

Secretary:

Helen Nolan

The present membership of the Board is set out on page 2.

In accordance with the Articles of Association, every year, one-third of the directors for the time being, or, if their number is not three or a multiple of three, then the number nearest one-third shall retire from office.

It has been agreed that on appointment, Directors will receive briefing and comprehensive documents designed to familiarise them with the company's operations, management and governance.

DIRECTORS' AND SECRETARY'S INTERESTS IN SHARES

The directors and secretary of the company who held office at 31 December 2021, had no interests in the shares of the company.

DIRECTORS' REPORT (CONTINUED)

DIRECTORS' INTERESTS IN CONTRACTS

There were no contracts or arrangements in relation to the company's business in which the directors or Secretary of the company had any interest.

POLITICAL CONTRIBUTIONS

There were no political donations made during the financial year (2020: €Nil).

ACCOUNTING RECORDS

The measures that the directors have taken to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of adequate accounting records, are the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The company's accounting records are maintained at the company's registered office at Harold's Cross, Dublin 6W.

DISCLOSURE OF INFORMATION TO AUDITORS

In the case of each of the persons who are directors at the time the directors' report and financial statements are approved:

- a) So far as the director is aware, there is no relevant audit information of which the company's statutory auditors are unaware; and
- b) Each director has taken all steps that ought to have been taken by the director in order to make himself/herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

DIRECTORS' COMPLIANCE POLICY STATEMENT

The directors acknowledge that they are responsible for securing compliance by the company with its relevant obligations as outlined in the Companies Act 2014 (the 2014 Act).

The directors confirm:

- (a) that a compliance policy statement, setting out the company's policies that, in the directors' opinion, are appropriate to the company regarding compliance by the company with its relevant obligations (within the meaning of the 2014 Act) has been drawn up;
- (b) appropriate arrangements or structures that are, in the directors' opinion, designed to secure material compliance with the company's relevant obligations have been put in place; and
- (c) a review of those arrangements and structures has been conducted during the financial year.

The arrangements and structures include reliance on the assistance and advice of persons employed by the company and by external legal, compliance and tax advisors that the directors consider to have the requisite knowledge and experience to advise on the company's compliance with its relevant obligations.

DIRECTORS' REPORT (CONTINUED)

AUDITORS

The auditors, Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, continue in office in accordance with Section 383(2) of the Companies Act 2014.

Approved by the Board and signed on its behalf by:

Lorcan Birthistle

Director

Helen Nolan Director

DIRECTORS' RESPONSIBILITIES STATEMENT

The directors are responsible for preparing the directors' report and the financial statements in accordance with the Companies Act 2014.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council ("relevant financial reporting framework"). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the directors are required to:

- select suitable accounting policies for the Company Financial Statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Legislation in Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website.

Deloitte

Deloitte Ireland LLP Chartered Accountants & Statutory Audit Firm

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF OUR LADY'S HOSPICE & CARE SERVICES

Report on the audit of the financial statements

Opinion on the financial statements of Our Lady's Hospice & Care Services (the 'company') In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2021 and of the net income for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework and, in particular, with the requirements of the Companies Act 2014.

The financial statements we have audited comprise:

- the Statement of Financial Activities;
- the Balance Sheet;
- · the Statement of Cash Flows; and
- the related notes 1 to 33, including a summary of significant accounting policies as set out in note 1.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council ("the relevant financial reporting framework").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Reports and Financial Statements for the financial year ended 31 December 2021, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the Reports and Financial Statements for the financial year ended 31 December 2021. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Deloitte

/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF OUR LADY'S HOSPICE & CARE SERVICES

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Report on the audit of the financial statements (Continued)

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

a98202dc9c3a/Description of auditors responsibilities for audit.pdfr.

This description forms part of our auditor's report.

Report on other legal and regulatory requirements

Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements and the directors' report has been prepared in accordance with the Companies Act 2014.

Continued on next page/

Deloitte.

/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF OUR LADY'S HOSPICE & CARE SERVICES

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

David Boyle

For and on behalf of Deloitte Ireland LLP Chartered Accountants and Statutory Audit Firm Deloitte & Touche House, Earlsfort Terrace, Dublin 2

Date: 1 July 2022

STATEMENT OF FINANCIAL ACTIVITIES FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

	Notes	Unrestricted	Restricted	Total	Unrestricted	Restricted	Total
		€ 2021	€ 2021	€ 2021	€ 2020	€ 2020	€ 2020
INCOME FROM							
Donations and							
legacies	4	4,174,058	2,688,794	6,862,852	4,255,574	495,826	4,751,400
Charitable activities	5	180,083	44,751,813	44,931,896	3,895,456	44,992,937	48,888,393
Investment income	6	16,222	-	16,222	4,644	-	4,644
Other trading							
activities	7	292,734	-	292,734	320,111		320,111
TOTAL INCOME		4,663,097	47,440,607	52,103,704	8,475,785	45,488,763	53,964,548
EXPENDITURE ON							
Raising funds	8	1,554,626	391,091	1,945,717	1,511,437	405,512	1,916,949
Charitable activities	9	3,679,253	45,549,313	49,228,566	3,611,565	41,811,057	45,422,622
					- Control of the Cont		***************************************
TOTAL							
EXPENDITURE		5,233,879	45,940,404	51,174,283	5,123,002	42,216,569	47,339,571
Net (expenditure)/ income before other recognised gain/(loss)		(570,782)	1,500,203	929,421	3,352,783	3,272,194	6,624,977
Gain/(loss) on financial assets at							
fair value	11	9,274		9,274	(38,099)	**	(38,099)
Net (expenditure)/ income before							
taxation	11	(561,508)	1,500,203	938,695	3,314,684	3,272,194	6,586,878
Taxation	13					-	-
NET INCOME		(561,508)	1,500,203	938,695	3,314,684	3,272,194	6,586,878
Transfer between							
funds Total funds at	14	•	-	-	-	-	-
beginning of							
financial year		32,861,267	25,497,553	58,358,820	29,546,583	22,225,359	51,771,942
Total funds at end of							
financial year		32,299,759	26,997,756	59,297,515	32,861,267	25,497,553	58,358,820

There were no recognised gains or losses other than those listed above and the net movement in funds for the financial year. All income and expenditure derives from continuing activities.

BALANCE SHEET AS AT 31 DECEMBER 2021

	Notes	2021 €	2020 €
Fixed assets			
Tangible assets	16	85,784,184	87,771,195
Financial assets	17	170,985	170,226
		85,955,169	87,941,421
Current assets			
Stocks	18	524,135	409,816
Debtors: amounts falling due within one year	19	7,088,128	6,161,465
Investment	20	26,220	233,073
Cash at bank and on hand	21	14,731,264	10,335,358
		22,369,747	17,139,712
Creditors: (amounts falling due within one year)	22	(8,024,735)	(5,469,957)
Net current assets		14,345,012	11,669,755
Total assets less current liabilities		100,300,181	99,611,176
Creditors: (amounts falling due after more than on	e year) <i>23</i>	(2,363,878)	(2,613,568)
NET ASSETS		97,936,303	96,997,608
Capital and charity funds		And the second second second second	estandamentenia — a consensatoria de himad
Called up share capital	24	2	2
Share premium	24	38,638,786	38,638,786
Restricted capital funds	29	25,754,169	24,255,062
Restricted funds	29	1,243,587	1,242,491
Unrestricted funds	29	32,299,759	32,861,267
CHARITY FUNDS		97,936,303	96,997,608

The financial statements were approved and authorised for issue by the Board of directors on and signed on its behalf by:

Lorcan Birthistle

Director

Helen Nolan Director

OUR LADY'S HOSPICE & CARE SERVICES STATEMENT OF CASH FLOWS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

	Notes	2021 €	2020 €
Net cash inflow from operating activition	es 25	5,413,717	3,558,355
			
Cash flows from investing activities			004
Interest and similar income received		(424.264)	894
Interest paid		(134,364)	(41,269
Payments to acquire tangible fixed asser	ts	(1,000,384)	(1,362,105
Payments to acquire financial assets		407 500	(40
Proceeds from sale of fixed assets		137,599	1 464 33
HSE capital grant received		-	1,464,337
Proceeds on disposal of financial assets		24,737	26,936
Disposal / (acquisition) of investment		206,853	(25,233
Net cash flows from investing activities	i	(765,559)	63,520
Cash flows from financing activities			<u></u>
Bank loan received for Wicklow Hospice	!	•	2,868,085
Bank loan repaid		(252,252)	(2,868,085
Net cash flows from financing activities		(252,252)	
Net increase in cash and cash equivaler	nts	4,395,906	3,621,875
Cash and cash equivalents at beginning	of financial year	10,335,358	6,713,483
Cash and cash equivalents at end of fin	ancial year	14,731,264	10,335,358
		The state of the s	****
Reconciliation to cash and cash equival	ents		
Cash at bank and in hand		14,731,264	10,335,358
Analysis of changes in net debt			300,000,000,000,000,000,000,000,000,000
Allalysis of changes in het debt	At 1/1/2021	Cashflows	At 31/12/2021
	€	€	(
Cash and Cash Equivalents	•		
Cash (company funds)	10,141,688	4,401,172	14,542,862
Funds held on behalf of 3 rd party funds	193,670	(5,268)	188,402
	10,335,358	4,395,904	14,731,264
	Add 1 (4 A 1 A 1 A 1 A 1 A 1 A 1 A 1 A 1 A 1 A		
Borrowings			•===
Debt due within one year	(254,517)	2,562	(251,955
Debt due after one year	(2,613,568)	249,690	(2,363,878
	(2,868,085)	252,252	(2,615,833
Total	7,467,273	4,648,156	12,115,433

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES

The significant accounting policies adopted by the company are set out below. These policies have been consistently applied to all financial years presented unless otherwise stated.

General Information and Basis of Financial Statements Presentation

Our Lady's Hospice & Care Services is a company incorporated in Ireland under the Companies Act 2014. The company number is 352404 and the address of the registered office is Harold's Cross, Dublin 6W.

The objectives of the company are charitable in nature and it has been granted charitable tax exemption by the Revenue Commissioners (Charity number CHY1144) and is registered with the Charities Regulatory Authority (CRA number 20001827). The company's operations and its principal activities are set out in the directors' report on pages 3 to 14.

In accordance with Section 1180(8) of the Companies Act, 2014, the company is exempt from including the word "Limited" in its name. The company is a designated activity company limited by shares (DAC) under Part 16 of the Companies Act 2014.

The company has adopted and reported its performance in accordance with the format provided for in the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" as published by the Charity Commission for England and Wales.

The Charity Commission for England and Wales, is recognised by the UK accounting Standards Board (ASB) as the appropriate body to issue SORP's for the charity sector in the UK, and the SORP has heretofore been recognised as best practice for financial reporting by Charities in Ireland.

The financial statements have been prepared in accordance with the Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Basis of Accounting

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued by the Financial Reporting Council and the Companies Act 2014. The financial statements are presented in euro.

The financial statements are prepared on a going concern basis of accounting in preparing these financial statements, as detailed further in note 2.

Tangible Fixed Assets and Depreciation

Tangible fixed assets are carried at cost (or deemed cost) less accumulated depreciation and accumulated impairment losses. Cost includes the original purchase price, costs directly attributable to bringing the asset to the location and condition necessary for its intended use, applicable dismantling, removal and restoration costs. Tangible fixed assets where the cost is less than €7,000 are expensed, and less than €2,000 for computer equipment.

ACCOUNTING POLICIES (CONTINUED) 1.

Tangible Fixed Assets and Depreciation (Continued)

Land and buildings include freehold properties. Land and buildings are carried at cost. Fixtures and fittings and motor vehicles are carried at cost less accumulated depreciation and accumulated impairment losses.

Subsequent additions are included in the assets carrying amount or recognised as a separate asset, as appropriate, only when it is probable that the economic benefits associated with the asset will flow to the company and the cost can be reliably measured. Assets in the course of construction are carried at cost. Major components are treated as separate assets where they have significantly different patterns of consumption of economic benefits and are depreciated separately over their useful lives.

Donated assets are recognised as tangible fixed assets when their fair value exceeds the above mentioned thresholds. Donated assets held as tangible fixed assets are subject to depreciation except in cases where they are held for resale and not used in the period in which case they are not depreciated.

Land is not depreciated. Assets under construction are not depreciated until they are available for use. Depreciation on other tangible assets is provided at rates calculated to write off the cost of the assets over their estimated useful lives. The rates and methods of depreciation are as follows:

Building Fixtures and equipment Motor Vehicles Computer equipment	2% 15% 20% 33%	straight line straight line straight line straight line
Computer equipment		

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Repairs and maintenance costs are expensed as incurred.

Impairment of Assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Financial Activities as described below.

An asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced to below its carrying amount. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES (CONTINUED)

Pensions

The company operates a defined benefits pension scheme in respect of employees eligible for inclusion under the Voluntary Hospitals Superannuation Scheme. The scheme is administered, funded and underwritten by the Department of Health. The company acts as agents in the operation of the scheme and does not make any contributions to the scheme.

Contributions are received from eligible employees only. In accordance with the service plan agreed with the HSE and the Department of Health, pension contributions received may be offset against pension payments made and the surplus or deficit each financial year forms part of the funding for the company. The directors consider that the company has no responsibility for any liability that falls due as a result of any ultimate under funding of the scheme.

Contributions received are credited to the Statement of Income and Retained Earnings as they are received. Payments made under the scheme are charged to the Statement of Income and Retained Earnings as they fall due. Refunds of Contributions are charged to the Statement of Income and Retained Earnings when notification is received from the Department of Health to make a payment to an employee who is leaving the scheme.

A new Single Public Service Pension Scheme (Single Scheme) commenced with effect from 1st January 2013. The Scheme applies to all pensionable first time entrants to the Public Service, as well as former public servants returning to the Public Service after a break of more than 26 weeks. Benefits are calculated by reference to "referable amounts" for each year's service that are uprated by the CPI as notified by the Minister. All contributions deducted from members wages/salaries are remitted to the nominated bank account of the Department of Public Expenditure and Reform and not credited to the Profit and Loss Account. As per Public Service Pensions (Single Scheme and Other Provisions) Act 2012, Section 44(1) (b), payments arising under this Single Scheme to retiring employees shall be paid from funds provided by the Oireachtas for that purpose.

Certain company employees are members of a defined contribution pension scheme and the assets of the scheme are held separately from those of the company. The annual contributions payable are charged to the Statement of Financial Activities.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost is determined by reference to invoice price including charges such as freight and duty as appropriate. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES (CONTINUED)

Foreign Currencies

The functional and presentational currency of the company is considered to be Euro because that is the currency of the primary economic environment in which the company operates.

Transactions in foreign currencies are recorded at the rate ruling at the date of the transactions. The resulting monetary assets and liabilities are translated at the balance sheet rate and the exchange differences are dealt with in the Statement of Financial Activities.

Income – Donations and legacies, charitable activities (HSE and other grants), investment and other trading activities

Income is the amount derived from the provision of services. Turnover comprises income from patients (directly and from Private Health Insurers), income from fundraising activities and events, income from the hire of facilities and other income.

- (i) Income from voluntary donations is recognised when received. As with many similar charitable organisations, independent groups from time to time organise fundraising activities and may operate bank accounts in the name of Our Lady's Hospice & Care Services. However, as amounts collected in this way are outside the control of the company, they are not included in the financial statements until received by Our Lady's Hospice & Care Services.
- (ii) Proceeds from the sale of donated goods are recognised in the financial statements in the period in which they are realised. Volunteer time is not included in the financial statements.
- (iii) Grants from the HSE, government and other agencies have been included as income from activities in furtherance of the charity's objects and accounted for on a receivable basis. Revenue grants received and receivable from the HSE are accounted for on the basis of the allocated amount notified by the HSE for that financial year. Capital grants received are recognised as income in the financial year and the depreciation on the related capital asset is charged against the restricted capital fund.
- (iv) Legacies are included when the company is entitled to the legacy, the amount can be measured and it is probable that the company will receive.
- (v) Donations in kind may take the form of property provided to the company free of charge. Where title has transferred and valuation can be measured with reasonable certainty, donations in kind are recognised in full as income in the year of receipt. Donations in kind are valued based on a professional valuation. If such a valuation is not available, reasonable prevailing market values are used.
- (vi) Investment income is recognised on a receivable basis.
- (vii) Patient income comprises income from patients directly and from Private Health Insurers (PHIs) and is recognised on a receivable basis.
- (viii) Other trading activities income comprises income from canteen, shop, coffee shop, rental and educational income is recognised on a receivable basis.

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES (CONTINUED)

Expenditure

Charitable activities comprise expenditure incurred by the activities in the Harold's Cross and Blackrock Hospices as well as support costs incurred at headquarters that are directly related to the implementation of charities activities. Expenditure is recognised in the period to which it relates. Expenditure incurred but unpaid at the balance sheet date is included in accruals and other creditors. Expenditure on raising funds comprise all expenditure incurred by Our Lady's Hospice & Care Services on raising funds for the company's charitable activities.

Support costs are those functions that assist the work of the company but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the company's healthcare activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities. The bases on which support costs have been allocated are set out in note 10.

Funds Accounting

Funds held by the charity are classified as unrestricted and restricted. Unrestricted funds are funds which can be used in accordance with the charitable objects at the discretion of the Directors. Restricted funds are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Financial instruments

Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions of the instrument.

Financial liabilities are classified according to the substance of the contractual arrangements entered into.

(i) Financial assets and liabilities

Basic financial assets and liabilities are initially measured at transaction price (including transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a finance transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. These financial assets are subsequently measured at fair value and the changes in fair value are recognised in the Statement of Comprehensive Income, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are subsequently measured at cost less impairment.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES (CONTINUED)

Financial instruments (Continued)

(i) Financial assets and liabilities (Continued)

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the company, despite having retained some significant risks and rewards of ownership, has transferred control of the asset to another party and the other party has the practical ability to sell the asset in its entirety to an unrelated third party and is able to exercise that ability unilaterally and without needing to impose additional restrictions on the transfer.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Financial assets and liabilities are only offset in the balance sheet when and only when there exists a legally enforceable right to set off the recognised amounts and the company intends either to settle on a net basis, or to realise the assets and settle the liability simultaneously.

Balances are classified as payable or receivable within one year if payment or receipt is due within one year or less. If not, they are presented as falling due after more than one year. Balances that are classified as payable or receivable within one year on initial recognition are measured at the undiscounted amount of the cash or other consideration expected to be paid or received, net of impairment.

Taxation

The company has been granted charitable tax exempt status by the Revenue Commissioners under CHY number 1144 and therefore no provision for Corporation tax is required.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

2. GOING CONCERN

The company's business activities, together with the factors likely to affect its future development, performance and position are set out in the directors' report.

The financial statements have been prepared on the going concern basis. The company is dependent on the Health Service Executive (HSE) to fund its activities and the ongoing support of the HSE at an appropriate level is fundamental to the company's ability to continue as a going concern. The HSE has not given any indication that it will withdraw its financial support from the company for the foreseeable future and has continued to provide funding for 2022. The HSE has indicated that funding will be available during 2022 at a level similar to that of 2021.

During 2021 Ireland continued to be impacted by the COVID pandemic. The directors have again considered the COVID impact on the company, and they recognise that there is still a risk that fundraising activities may continue to be disrupted or curtailed by the ongoing impact of the pandemic.

While our organisation has shown great resilience in terms of our fundraising ability over the last 26 months or so since the first closures arising from Covid 19, we continue to operate in a challenging fundraising environment. Our fundraising income held up very well during 2021, and while we continue to be conservative in our estimates of fundraising income for 2022 and 2023 due to the ongoing curtailment of certain in-person events and activities, we are optimistic that the lost income from such in-person events will be lower in 2022 and 2023 than the preceding two years. We are also conscious that other world events and fundraising campaigns around for example the Ukraine crises may impact on our donor pool.

Funding pressures and breaking even on HSE funded activities remain a concern, especially in relation to reduced private health insurance income which improved marginally on 2021 but is still almost €1.8m below pre pandemic levels. This is coupled with an increased demand for the company's services. Management have reviewed the level of activity and costs of the company and have drawn up plans to deal with the issues associated with the ongoing funding pressures. The company's current operating budget and forecast (assuming no reduction in HSE Funding) show that the company should be able to operate within its available funding for the foreseeable future (at least twelve months from the date of approval of these financial statements).

While the strong reserves position at year-end means that there is no immediate threat to the going concern status of OLH&CS, provision of services remains reliant on funding from the HSE continuing at the same or enhanced levels in the future.

After making due enquiries, the directors have a reasonable expectation that the operating and capital budgets and plans will be achieved and that the company will have adequate resources and sufficient liquidity to continue to operate for the foreseeable future. On that basis, the directors have continued to adopt the going concern basis of accounting in preparing these financial statements.

The ongoing support of the HSE at an appropriate level and the generosity of the public are fundamental to the achievement of these plans.

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the company's accounting policies, which are described in note 1, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is included in the accounting policies and the notes to the financial statements.

(a) Critical judgement in applying the company's accounting policies

The following judgement, apart from those involving estimates, made by the directors has had significant effect on the amounts recognized in the company's financial statements:

(i) Pensions

Certain employees participate in the VHSS operated by the HSE. The VHSS is an unfunded 'pay as you go' scheme underwritten by the Minister for Health and Children. In the judgement of the directors the funds required to pay current pension liabilities, under the VHSS, as they arise will continue to be provided by the Department of Health and Children. Therefore, they believe that it is not necessary for the financial statements to make provision for the net assets/liabilities at the balance sheet date in respect of pension entitlements accrued to that date by the employees of the company, nor the disclosure requirements of the Charities SORP (FRS102). See note 28 for further details.

(b) Critical accounting estimates and assumptions

The directors make estimates and assumptions concerning the future in the process of preparing the company's financial statements. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next financial year are addressed below.

(i) Useful economic lives of tangible fixed assets and residual value

The annual depreciation on tangible fixed assets is sensitive to changes in the estimated useful lives and residual values of the assets. The useful economic lives and residual values are reviewed annually. They are amended when necessary to reflect current estimates, based on economic utilisation, technological advancements and the physical condition of the assets. The amortisation rate for capital grants is also reviewed in conjunction with the asset lives review and these are adjusted if appropriate.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY (CONTINUED)

(b) Critical accounting estimates and assumptions (continued)

(ii) Impairment of debtors

The directors make an assessment at the end of each financial year of whether there is objective evidence that a debtor is impaired. When assessing impairment of debtors and other amounts receivable, the directors consider factors including the age profile of outstanding amounts receivable, recent correspondence and historical experience in cash collectors from debtors.

4. DONATIONS AND LEGACIES

	2021 Unrestricted €	2021 Restricted €	Total €	2020 Unrestricted €	2020 Restricted €	Total €
Legacy and						
Bequest Income	1,253,037	283,458	1,536,495	1,302,944	1,968	1,304,912
Donations	2,921,021	2,405,336	5,326,357	2,952,630	493,858	3,446,488
	4,174,058	2,688,794	6,862,852	4,255,574	495,826	4,751,400

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

5. CHARITABLE ACTIVITIES

	2021	2021		2020	2020	
Unr	estricted	Restricted	Total	Unrestricted	Restricted	Total
	€	€	€	€	€	€
HSE Respite Bed Income	-	56,100	56,100	-	33,700	33,700
VAT Compensation Scheme Gift in Kind Income	42,014	-	42,014	27,423	**	27,423
(re Wicklow Hospice, Note 3 HSE Capital Grants	•	-	-	3,733,883	1,250,000	4,983,883
(Wickow Hospice, COVID-19	ward					
& Energy grant)	~	-	-	-	1,464,377	1,464,377
NMPDU Grants	-	-	-	-	37,500	37,500
TUSLA Grant	-	-	-	-	24,600	24,600
HSE Grants for patient Care	-	36,334,172	36,334,172		33,992,628	33,992,628
HSE Fair Deal Income	-	3,354,131	3,354,131	-	3,373,787	3,373,787
Patient Income Conferences, seminars,	-	3,307,316	3,307,316	-	3,162,788	3,162,788
research income	138,069	-	138,069	134,150	-	134,150
Superannuation Income		958,510	958,510	-	958,835	958,835
Pension Levy Income	-	741,584	741,584	*	694,762	694,762
-		energy and the second of the s			Market	
	180,083	44,751,813	44,931,896	3,895,456	44,992,937	48,888,393

6. INVESTMENT INCOME – UNRESTRICTED

20 Unrestric	021 ted €	2021 Restricted €	Total €	2020 Unrestricted €	2020 Restricted €	Total €
Income from financial assets	-	-	_	-	875	875
Interest received	•	-	***	19	-	19
	-	-	-	894		894
Profit on sale of investments 16,7	222	-	16,222	3,750	-	3,750
Total Investment Income 16,2	222	-	16,222	4,644	-	4,644

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

7.	OTHER TRADING ACTIV	/ITIES					
		2021	2021		2020	2020	
	Unre		Restricted	Total	Unrestricted	Restricted	Total
		€	€	€	€	€	€
	Other Trading Income	292,734	-	292,734	320,111		320,111
		292,734	-	292,734	320,111		320,111
							PROPERTY OF THE PROPERTY OF TH
8.	EXPENDITURE ON RAIS	ING FUNDS				·	
		2021		2021	2020		2020
		Direct	Support		Direct	Support	
		Costs	Costs	Total	Costs	Costs	Total
		€	€	€	€	€	€
	Salaries and other fundraising costs	1,133,567	909	1,134,476	1,155,723	2,630	1,158,353
	Bank interest and charges	125,825	-	125,825	30,415	-	30,415
	Expenses from trading activity	683,824	-	683,824	725,623	-	725,623
	Investment manageme fees	ent 1,592	-	1,592	2,558	-	2,558
	Total Cost of Raising						
	Funds	1,944,808	909	1,945,717	1,914,319	2,630	1,916,949
		2021		2021	2020		2020
	Funded from: U	nrestricted	Restricted		Unrestricted	Restricted	Total
		€	€	€	€	€	€
	Fundraising costs Expenses from other	1,260,300	-	1,260,300	1,188,768	-	1,188,768
	trading activities Investment manageme	292,734 ent	391,091	683,825	320,111	405,512	725,623
	fees	1,592	•	1,592	2,558	_	2,558
	Total Cost of Raising Funds	1,544,626	391,091	1,945,717	1,511,437	405,512	1,916,949

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

9. EXPENDITURE ON CHARITABLE ACTIVITIES

	2021 Direct	Support	2021	2020 Direct	Support	2020
	Costs €	Costs €	Total €	Costs €	Costs €	Total €
Palliative Care	22,991,047	809,891	23,800,938	19,536,087	816,369	20,352,456
Community Reablement Unit, CRU Care of Older People	3,365,360	120,961	3,486,321	2,601,801	121,902	2,723,703
in Anna Gaynor House Rheumatic &	15,780,348	714,512	16,494,860	15,812,562	719,745	16,532,307
Musculoskeletal Disease Unit, RMDU	4,658,322	232,273	4,890,595	5,107,832	234,045	5,341,877
	46,795,077	1,877,637	48,672,714	43,058,282	1,892,061	44,950,343
Bank Interest and Charges	8,539		8,539	10,854	<u>.</u>	10,854
Patient Care and Services	46,803,616	1,877,637	48,681,253	43,069,136	1,892,061	44,961,197
Education & Training	547,313	-	547,313	461,425	-	461,425
Total Charitable Expenditure	47,350,929	1,877,637	49,228,566	43,530,561	1,892,061	45,422,622
Funded from:	2021 Unrestricted €	Restricted €	2021 Total €	2020 Unrestricted €	Restricted €	2020 Total €
Patient Care &						
Services Education & Training		45,549,313 -	48,681,253 547,313	3,150,140 461,425	41,811,057	44,961,197 461,425
Total Charitable Expenditure	3,679,253	45,549,313	49,228,566	3,611,565	41,811,057	45,422,622

OUR LADY'S HOSPICE & CARE SERVICES

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

10. ANALYSIS OF GOVERNANCE AND SUPPORT COSTS

	Charital	Charitable Activities		Raisi	Raising Funds		Basis of
	General Support	Governance Function	Total	General Support	Governance Function	Total	Apportionment of Charitable Activities
2021	· w	Ψ	Ψ	ω	Ψ	Ę	
Payroll costs	1,561,489	ı	1,561,489	1	1	4	Direct labour costs
General support costs	284,928	ŧ	284,928	ţ.	ı	ľ	Direct labour costs & beds
and regulatory costs	i	31,221	31,221	1	606	606	Beds
Total Support Costs	1,846,417	31,221	1,877,638	*	606	606	
	The state of the s			The state of the s	200		
2020							
Payroll costs	1,575,913	ı	1,575,913	ī	1	ŀ	Direct labour costs
General support costs	240,357	ı	240,357	•	t	t	Direct labour costs & beds
and regulatory costs	ı	75,791	75,791	•	2,630	2,630	Beds
Total Support Costs	1,816,270	75,791	1,892,061		2,630	2,630	
					Adda.		

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

11.	NET INCOME BEFORE TAXATION	2021	2020
		€	€
	The net income before taxation for		
	the financial year has been arrived at		
	after charging / (crediting):		
	Depreciation	2,847,395	2,819,289
	Directors' remuneration	•	-
	Auditors' remuneration	31,350	30,650
	Cost of stock recognised as expense	723,828	741,252
	Gain on sale of investments	(16,222)	(3,750)
	(Gain)/loss on fair value movement of financial assets (Note 17)	(9,274)	38,099
	(a) Auditors' remuneration disclosures (net of Vat and outlays):	31,350	30,650
	Audit	31,330	30,030
	Other non-audit	-	-
		31,350	30,650
		31,330	30,030
	(b) Medical Worker Directors		MATERIAL AND A SECURE OF THE PROPERTY OF THE P

(b) Medical Worker Directors

No salaries or fees are payable to the directors of the company for their services as directors.

12. INTEREST PAYABLE AND SIMILAR CHARGES

			Total			Total
	Healthcare	Development 2021 Healthcare Development		evelopment	2020	
	€	€	€	€	€	€
On bank loans, overdr and other loans wholl repayable within five						
years	(8,539)	(125,825)	(134,364)	(10,854)	(30,415)	(41,269)

13. TAXATION

As a result of the company's charitable status, no charge to corporation tax arises.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

14. TRANSFER BETWEEN FUNDS

Similar to the prior year there is a transfer of funds of €61, 447 from capital restricted fund balances to restricted funds in relation to small expenditure items.

In the prior year €173,439 of funds were transferred from capital restricted fund balances to restricted funds in relation to expenditure items within the 2019 €300k Wicklow grant being non-capital in nature. There was also a small transfer from restricted funds to restricted capital funds of €1,850.

15. STAFF NUMBERS AND COSTS

The average number of persons employed by the company during the financial year was as follows:

				2021	L	2020
				No	•	No.
Management and sta	iff (whole time o	equivalents)		553	.	531
					=	
The aggregate payrol	I costs of these	persons were	e as follows:			
			Total			Total
	Healthcare D	evelopment	2021	HealthcareD	evelopment	2020
	€	€	€	€	. €	€
Wages and salaries	31,107,084	2,174,428	33,281,512	28,373,617	2,103,390	30,477,007
Social welfare costs	3,273,578	68,290	3,341,868	3,051,001	71,431	3,122,432
Superannuation	3,143,903	-	3,143,903	2,546,135	u u	2,546,135
Pension costs	-	137,278	137,278	-	133,557	133,557
	37,524,565	2,379,996	39,904,561	33,970,753	2,308,378	36,279,131

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

15. STAFF NUMBERS AND COSTS (CONTINUED)

Key management compensation

The total remuneration for key management personnel for the financial year amounted to €648,300 (2020: €644,621), and this includes gross salary, ER PRSI, and pension contribution. This reflects both healthcare and fundraising activities.

The gross pay of the CEO for the year was €124,433 (2020: €121,460).

The number of employees, including medical staff, whose emoluments, excluding pension contributions, were in excess of €60,000:

	2021	2020
	No.	No.
€60,000 - €69,999	97	85
€70,000 - €79,999	30	24
€80,000 - €89,999	8	7
€90,000 - €99,999	3	3
€100,000 - €109,999	-	1
€110,000 - €119,999	1	1
€120,000 - €129,999	1	1
€150,000 - €159,999	2	-
€170,000 - €179,999	1	1
€180,000 - €189,999	1	1
€220,000 - €229,999	-	1
€230,000 - €239,999	1	-
€240,000 - €249,999	-	2
€270,000 - €279,999	1	•
€280,000 - €289,999	1	-
€300,000 - €309,999	-	1

All pay is aligned with the Department of Health Consolidated Pay Scales. During 2021 there were further pay increases in line with national pay agreements as reflected in the salary and wages bands above.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

16.	TANGIBLE FIXED ASSET	·s					
			Donated		Equipment	Motor	Total
		Land		Buildings	& Computer	Vehicles	
			eld for resal		Equipment	_	_
		€	€	€	€	€	€
	Cost or Valuation:						
	At 1 January 2021	11,036,500	500,000	100,880,995	13,573,791	140,179	126,131,465
	Additions	_	-	383,656	530,828	85,900	1,000,384
	Disposals	144	(140,000)	-	-	-	(140,000)
	At 31 December 2021	11,036,500	360,000	101,264,651	14,104,619	226,079	126,991,849
	Depreciation:						
	At 1 January 2021		-	26,854,921	11,368,308	137,041	38,360,270
	Charge for financial year	ir -	u.	1,996,246	823,373	27,776	2,847,395
	At 31 December 2021		**************************************	28,851,167	12,191,681	164,817	41,207,665
	Net Book Value:						
	At 31 December 2021	11,036,500	360,000	72,413,484	1,912,938	61,262	85,784,184
	At 31 December 2020	11,036,500	500,000	74,026,074	2,205,483	3,138	87,771,195

Donated properties held for resale comprise of one property that was estimated by Our Lady's Hospice & Care Services at €360,000 based on prevailing market values. The disposal relates to one property that was sold during the year.

17.	FINANCIAL ASSETS	2021 €	2020 €
	Listed investments:		
	Carrying amount at 1 January	170,226	231,471
	Additions	-	40
	Disposals	(8,515)	(23,186)
	At 31 December	161,711	208,325
	Movement in the fair value of listed investments	9,274	(38,099)
	Investment Portfolio	170,985	170,226

The fair value of listed investments was determined with reference to the quoted market price at the reporting date. The cost of the investments on acquisition was €111,298 (2020: €119,812).

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

	STOCKS	2021	2020
.8.	STOCKS	€	€
	Pharmacy	119,058	111,080
	Stores	405,077	298,736
		524,135	409,816
	There are no material differences between the replacement co	est of stock and the bala	nce sheet amou
		2024	2020
9.	DEBTORS: Amounts falling due within one year	2021 €	2020 €
	HSE	4,051,778	3,901,183
	Patient income	1,990,527	947,702
	Other debtors	773,588	1,132,525
	Prepayment	272,235	180,056
		7,088,128	6,161,465
		• •	• •
		Approximate the state of the st	
	Included in Other debtors is a balance of €377,000 (2020: €8.	The state of the s	
0.		The state of the s	acy income due.
0.	Included in Other debtors is a balance of €377,000 (2020: €8: INVESTMENT	27,000) relating to lega	acy income due.
0.		27,000) relating to lega 2021	acy income due. 2020
	INVESTMENT Short-term deposits held as part of trading portfolio	27,000) relating to legar 2021 € 26,220	2020 2033,073
	INVESTMENT	27,000) relating to legar 2021 € 26,220	2020 233,073
	INVESTMENT Short-term deposits held as part of trading portfolio	27,000) relating to legar 2021 € 26,220	2020 233,073
	INVESTMENT Short-term deposits held as part of trading portfolio CASH AT BANK AND ON HAND Funds held on behalf of patients (patient private property	27,000) relating to legal 2021 € 26,220 2021 €	2020 233,073
	INVESTMENT Short-term deposits held as part of trading portfolio CASH AT BANK AND ON HAND Funds held on behalf of patients (patient private property account) (Note 22)	27,000) relating to legal 2021 € 26,220 2021 € 120,884	2020 233,073 2020 247,010
0 .	INVESTMENT Short-term deposits held as part of trading portfolio CASH AT BANK AND ON HAND Funds held on behalf of patients (patient private property	27,000) relating to legal 2021 € 26,220 2021 €	
	INVESTMENT Short-term deposits held as part of trading portfolio CASH AT BANK AND ON HAND Funds held on behalf of patients (patient private property account) (Note 22) Funds held on behalf of Together for Hospice (Note 22)	27,000) relating to legal 2021 € 26,220 2021 € 120,884 67,518	2020 233,075 2020 247,016 46,65

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

22.	CREDITORS: Amounts falling due within one year	2021 €	2020 €
	Trade creditors	1,865,335	1,078,876
	Accruals	3,394,854	2,732,065
	Other creditors	484,233	435,838
	PAYE/PRSI	1,839,956	774,991
	Funds held on behalf of third parties (Note 21)	188,402	193,670
	Bank loan (Note 23)	251,955	254,517
		8,024,735	5,469,957

Securities

The company's borrowings have been secured by a first mortgage/fixed charge over the company's Wicklow Hospice property at Magheramore, County Wicklow, along with a floating charge on all other property. This charge is held in favour of Bank of Ireland principal moneys and interest.

There is a supplemental charge held in favour of the Health Service Executive over the company's Wicklow Hospice property at Magheramore, County Wicklow. This is in relation to a capital grant of €1,250,000 made previously by the Health Service Executive to the Wicklow Hospice Foundation.

23.	CREDITORS: Amounts falling due after more than one year	2021	2020
	-	€	€
	Bank loan	2,363,878	2,613,568
	Bank loan repayment analysis (Note 31):		
	Less than one year	251,955	254,517
	Between one and five years	1,090,531	1,056,921
	Over five years	1,273,347	1,556,647
		2,615,833	2,868,085

24.	CALLED-UP SHARE CAPITAL PRESENTED AS EQUITY	2021	2020
		€	€
	Authorised:		
	100,000 Ordinary shares of €1 each	100,000	100,000
	Allotted, called-up and fully paid equity shares:		The state of the s
	2 Ordinary shares of €1 each	2	2
	Presented as follows:		
	Called up share capital presented as equity	2	2

The company has one class of ordinary shares which carry no right to fixed income. The share premium reserve of €38,638,786 contains the premium arising on issue of equity shares on incorporation.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

25.	RECONCILIATION OF NET INCOME		
	TO NET CASH GENERATED BY OPERATIONS	2021	2020
		€	€
	Net income before taxation	938,695	6,586,878
	Investment income	(16,222)	(4,644)
	Interest payable and similar charges	134,364	41,269
	(Gain)/loss on financial assets at fair value	(9,274)	38,099
	Depreciation	2,847,395	2,819,289
	Gift in Kind recognised in Statement of Financial Activities	-	(4,983,883)
	Donated assets held for resale income	2,401	(500,000)
	Capital grant recognised in Statement of Financial Activities	-	(1,464,337)
	Operating cash flow before movement in working capital	3,897,359	2,532,671
	Increase in stock	(114,319)	(96,659)
	(Increase)/decrease in debtors	(926,663)	227,957
	Increase in creditors	2,557,340	894,386
	CASH GENERATED BY OPERATING ACTIVITIES	5,413,717	3,558,355

26. FINANCIAL INSTRUMENTS

The carrying values of the company's financial assets and liabilities are summarised by category below:

	2021	2020 €
	€	•
Financial assets		
Measured at fair value through profit or loss		470.226
 Financial asset listed investments (Note 17) 	170,985	170,226
Measured at undiscounted amount receivable		
Trade and other debtors (Note 19)	6,815,8 9 3	5,981,408
Investment (Note 20)	26,220	233,073
Financial liabilities		
Measured at undiscounted amount payable		
Trade and other creditors (Note 22)	2,349,568	1,514,714
 Funds held on behalf of third parties (Note 22) 	188,402	193,670
Measured at amortised cost		
Bank loan (Note 23)	2,615,833	2,868,085

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

26. FINANCIAL INSTRUMENTS (CONTINUED)

The company's income, gains and losses in respect of financial instruments are summarised as follows:

2021 2020 €

Fair value gains and losses

Gain/(loss) on financial assets (including listed investments) measured as fair value through Statement of Financial Activities

9,274

(38,099)

There were no derivative financial instruments outstanding at 31 December 2021 or 31 December 2020.

27. CREDIT, MARKET AND LIQUIDITY RISKS

Credit risk

The company manages its financial assets and liabilities to ensure it will continue as a going concern. The principal financial assets of the company are bank and cash balances, investments, and trade and other receivables, which represent the maximum exposure to credit risk in relation to financial assets. The principal financial liabilities of the company are bank overdraft and trade and other payables.

The credit risk within the company is primarily attributable to its trade receivables, cash at bank and investments. The amounts presented in the statement of financial position are net of provisions for impaired receivables, estimated by management, based on prior experience and their assessment of the current economic environment.

The credit risk on liquid funds is mitigated by the spreading of deposits over a number of financial institutions.

The credit risk on investments arising is managed by a reputable external investment manager whose investment policy is to invest over a broad range of equity securities of high quality. The risk is monitored by regular reporting by the investment manager to the company.

The exposure from trade and other receivables arises primarily from amounts due from health insurance companies.

Market risk

(i) Interest rate risk

The company uses the bank overdraft for short-term borrowings and a bank loan for long-term borrowings. As part of its risk management process, the company identified the risk of exposure on the bank overdraft to interest becoming unaffordable due to rate increases during the term of the bank overdraft facility.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

27. CREDIT, MARKET AND LIQUIDITY RISKS (CONTINUED)

(ii) Foreign currency exchange rate risk

Some portion of the company's investments is denominated in pounds sterling or US dollars. The company's functional currency is euro. The company has no material exposure to foreign currencies. The policy is to maintain no significant foreign currency exposure by the investment manager.

(iii) Price risk

The company is exposed to equity securities price risk. To manage its price risk arising from investments in equity securities, the company diversifies its portfolio.

(iv) Cash flow and Liquidity risk

The bank overdraft liquidity risk is managed by regular reviews of cash flow forecasts and regular monitoring of cash balances and short-term liquidity trends.

28. PENSION COMMITMENTS

The company administers a defined benefits pension scheme in respect of employees eligible for inclusion under the Voluntary Hospitals Superannuation Scheme (VHSS). The financial statements do not include pension liabilities and assets of those staff who are members of the Voluntary Hospitals Superannuation Scheme (VHSS), as required by Financial Reporting Standard 102 "Employee Benefits" (FRS102). The majority of staff are members of the VHSS, which the directors believe is a scheme underwritten by the Minister for Health.

The directors of the company believe that the funds required to pay current pension liabilities, under the VHSS, as they arise into the future, will be provided by the Department of Health. The directors have arrived at this opinion having taken account of precedent set on the closure of certain other Healthcare facilities in recent years where pension payments (including retirement lump sum payments) have been honoured by the Department of Health. Therefore, they believe that it is not necessary for the financial statements of the company to make provision against the net assets at the balance sheet date in respect of pension entitlements accrued to that date by employees of the company, nor the other disclosure requirements of FRS 102.

The VHSS closed to new members with effect from 31 December 2012. In the financial year ending 31 December 2021, €3,143,903 (2020: €2,546,135) was paid to pensioners of the VHSS scheme, of which €913,917 related to lump sum payments (2020: €519,762).

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

28. PENSION COMMITMENTS (CONTINUED)

Whilst the VHSS scheme is a defined benefit scheme, the company has availed of the multi-employer scheme exemption from the disclosure requirements relating to defined benefit schemes in FRS 102, on the grounds that the company's deemed contributions, as determined by the Department for Health, are set in relation to the current service period only (i.e. are not affected by a surplus or deficit relating to the past service of its own employees or any other members of the scheme). On this basis the scheme is considered for disclosure purposes as a defined contribution scheme and no further disclosures are required.

A new Single Public Service Pension Scheme (Single Scheme) commenced with effect from 1st January 2013. The Scheme applies to all pensionable first time entrants to the Public Service, as well as former public servants returning to the Public Service after a break of more than 26 weeks. Benefits are calculated by reference to "referable amounts" for each year's service that are uprated by the CPI as notified by the Minister. All contributions deducted from members wages/salaries are remitted to the nominated bank account of the Department of Public Expenditure and Reform and not credited to the Profit and Loss Account. As per Public Service Pensions (Single Scheme and Other Provisions) Act 2012, Section 44(1) (b), payments arising under this Single Scheme to retiring employees shall be paid from funds provided by the Oireachtas for that purpose.

The amount deducted from employees in 2021 and paid over to DPER amounted to €499,858 (2020: €397,307). The amount payable to DPER at the financial year end was €40,852 (2020: €33,608).

The company operates an externally operated defined contribution scheme. The pension cost is charged to the statement of financial activities in the financial year in which it arises €137,278 (2020: €133,557). There was an amount payable at the financial year end of €10,104 (2020: €9,484).

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

29.	FUN	NDS	ι	Jnrestric Fu	ted nds €		ricted Funds €	Rest Capital	ricted Funds €	Total Funds €
	(a)	Reconciliation of funds:			-		_			
		Fund balances at 1 January 2021			267 *	*1,24	2,491	24,25	5,062 5	8,358,820
		Net income resources		(561,5	508)	(6	0,351)	1,56	0,554	938,695
		Transfer of funds			-	6	1,447	(6	51,447)	-
	Fu	Fund balances at 31 December 2021		32,299,7	759	1,24	3,587	25,75	4,169 5	9,297,517
		Share capital and premium		38,638,7	788		-		- 3	8,638,788
		Total Charity Fund balances at 31 December 2021		70,938,5	546 °	*1,24	3,587	25,75	4,169 9	7,936,303
			Unrest	tricted	Restric	ted R	lestricte	ed Capita	al	Total
				Funds		ınds		Funds		Funds
				€		€		€		€
	(b)	(b) Analysis of net assets between for								
		Tangible fixed assets	64,43	31,230		-	21,35	2,954		85,784,184
		Financial assets	17	70,985		-		-		170,985
		Current assets	9,35	51,689	8,616	843	4,40	1,215		22,369,747
		Current liabilities	(65	51,479)	(7,373,	,256)		-		(8,024,735)
		Long-term liabilities	(2,36	53,878)		-		-		(2,363,878)
		Total Charity Fund balances								
		31 December 2021	70,93	38,547	1,243,	,587	25,75	4,169		97,936,303
	(c)	(c) Movements in funds:								
			В	alance	Inc	ome	Expen	diture	Transfers	Balance
				as at						as at
			01/01	/2021		_		_	•	31/12/2021
			20.6	• 700		€		€	€	€
		Share capital and premium		38,788	4 000	~	/E 22	4 COE)	-	38,638,788
		Unrestricted funds		51,267	4,663			(4,605)	- 61 //7	32,299,759 1,243,587
		Restricted funds		42,491	44,816			6,912)	61,447	1,243,367
		Restricted capital funds	24,2:	55,062	2,624	,040	(1,00	3,492)	(01,447	4,103
		Total Charity fund balances	96,99	97,608	52,103	,704	(51,16	5,009)	-	97,936,303

^{*} Of this restricted fund balance of €1,243,587 (2020: (€1,242,491)), the HSE restricted balance is €1,067,300 (2020: (€1,104,924)) while the donor related restricted balance is €176,287 (2020: €137,567).

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

29. FUNDS (CONTINUED)

in r	espect of prior financial year:							
	•	Unrestri	cted	Rest	ricted	Rest	ricted	Total
		Fu	ınds	ļ	Funds	Capital I	unds	Funds
			€		€		€	€
Fund balances at 1 January 2020		29,546	,583	* (10	0,602)	22,32	5,961 5	1,771,942
	Net income resources	3,314	,684	1,17	1,504	2,10	0,690	6,586,878
	Transfer of funds	,		-	1,589	(17	1,589)	-
						-		
Fui	nd balances at 31 December 2	020 32,861	,267	1,24	12,491	24,25	5,062 5	8,358,820
	Share capital and premium	38,638	,788		-		- 3	8,638,788

	Total Charity Fund balances	at						
	31 December 2020	71,500	,055	*1,24	2,491	24,25	5,062 9	6,997,608
						, ,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	-	'
		Unrestricted	Re			ed Capita	ıl	Total
		Funds		Funds		Funds		Funds
		€		€		€		€
(b)	Analysis of net assets between funds:							
	Tangible fixed assets	66,173,127		-	21,59	8,068		87,771,195
	Financial assets	170,226		-		-		170,226
	Current assets	8,598,465		384,254	2,65	6,994		17,139,713
	Current liabilities	(828,195)		641,763)		-		(5,469,958)
	Long-term liabilities	(2,613,568)	I	-		-		(2,613,568)
	Total Charity Fund balances	at						
	31 December 2020	71,500,055	1,3	242,491	24,25	5,062		96,997,608
			······			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
(c)	Movements in funds:				_			
		Balance		Income	Expen	diture	Transfers	Balance
		as at						as at
		01/01/2020		_		_	-	31/12/2020
				€		€	€	•
	Share capital and premium	38,638,788	_	-	/ -	-		38,638,788
	Unrestricted funds	29,546,583	•	475,785	-	31,101)		32,861,267
	Restricted funds	(100,602)		360,891		19,387)	171,589	1,242,491
	Restricted capital funds	22,325,961	3,:	127,872	(1,02	7,182)	(171,589)	24,255,062
	Total Charity fund balances	90,410,730	53,	964,548	(47,37	7,670)	-	96,997,608

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

30. COLLABORATIVE ARRANGEMENTS

All Ireland Institute of Hospice and Palliative Care

Our Lady's Hospice & Care Services is part of a Collaboration Agreement governing the All Ireland Institute of Hospice and Palliative Care (AIIHPC), along with 26 other parties.

The AIIHPC is a leading organisation with national and international influence driving excellence in palliative care. AIIHPC is a collaborative of hospices, health and social care organisations and universities on the island of Ireland. AIIHPC advances education, research and practice to improve the palliative care experience of people with life limiting conditions and their families.

As the palliative care sector's institute, AIIHPC involves service users, carers and communities in palliative care delivery and development; works to integrate palliative care across the health system so people are supported as early as possible; and supports the development of specialist palliative care services for everyone who needs them.

Our Lady's Hospice & Care Services holds the position of Host Institution for AIIHPC. On behalf of all parties, the Host Institution will provide administrative support to the AIIHPC on an agreed basis in consultation with the other parties. AIIHPC have separate governance structures, policies and financial management.

Separate to this collaboration agreement, Our Lady's Hospice & Care Services has a commercial rental agreement with AIIHPC to the value of €25,000 (2020: €25,000).

Together for Hospice - The National Hospice Movement

Our Lady's Hospice & Care Services acts as host site and administrator for Together for Hospice — The National Hospice Movement (TFH). TFH was previously known as Support your Local Hospice (SYLH). TFH coordinates two national fundraising campaigns: 'Hospice Sunflower Days' and 'Ireland's Biggest Morning for Hospice Together with Bewleys.' All monies raised locally through these campaigns by individual hospices and specialist palliative homecare providers remain locally within the individual groups.

As per notes 21 and 22, monies are held by Our Lady's Hospice & Care Services on behalf of TFH with a corresponding creditor. In its position as host site, Our Lady's Hospice & Care Services employs the TFH National Projects Manager but this is funded through TFH and all monies are reimbursed to Our Lady's Hospice & Care Services. Local hospices or specialist palliative homecare providers around Ireland pay a membership contribution to TFH which is then used to run and promote the above national events and to cover salary and other costs. Any remaining funds are for the future use of TFH. There is oversight of TFH through a Governance Committee whose members are two Voluntary Health Group (VHG) CEO's, of which Our Lady's Hospice & Care Services is one member, and two national representatives from local groups.

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

31. RELATED PARTY TRANSACTIONS

Wicklow Hospice Foundation (WHF) is a company limited by guarantee with no beneficial owners. WHF is a related party of the company as it has four common directors.

In 2020, ownership of the Wicklow Hospice land and buildings transferred from WHF to Our Lady's Hospice & Care Services. At that time a €750k loan to WHF, a €2.9m bank loan, and €0.1m in retention monies owing on the build were offset against the €8.75m value of the land and buildings, and €5m in gift-in-kind income was recognised.

32. CAPITAL COMMITMENTS

At the Balance Sheet date the company had capital expenditure amounting to:

	2021	2020
	€	€
Committed not contracted:	6,968,899	309,724
Contracted:	-	148,032
	6,968,899	457,756

33. POST BALANCE SHEET EVENTS

The directors have considered the impact of the situation arising from the invasion of Ukraine by Russia, and the consequent sanctions imposed on the latter, are generating impacts on the global economy that, at the date of preparation of these financial statements, are unpredictable.

In this context, the world economy is affected by the increase in the prices of certain goods and services. Management have, and will continue to, monitor these changes in the context of overall expenditure review and considerations.